<DOC>
	<DOCNO>NCT00238368</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Giving chemotherapy autologous stem cell bone marrow transplant may allow chemotherapy give cancer cell kill . Procedures , fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) ( do chemotherapy ) may help doctor predict patient 's risk relapse help plan best treatment . PURPOSE : This phase II trial study well FDG-PET work predict risk relapse patient aggressive non-Hodgkin 's lymphoma undergoing combination chemotherapy without autologous stem cell bone marrow transplant .</brief_summary>
	<brief_title>Fludeoxyglucose F 18 Positron Emission Tomography Predicting Risk Relapse Patients With Non-Hodgkin 's Lymphoma Who Are Undergoing Combination Chemotherapy With Without Autologous Stem Cell Bone Marrow Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine event-free survival patient aggressive non-Hodgkin 's lymphoma treat early high-dose therapy autologous peripheral blood stem cell ( PBSC ) bone marrow transplantation ( BMT ) base positive fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) result obtain first-line chemotherapy . - Compare event-free survival patient treat regimen historical event-free survival patient positive FDG-PET result obtain first-line chemotherapy treat early high-dose therapy . Secondary - Compare overall survival patient treated standard treatment regimen vs early high-dose therapy autologous PBSC BMT base FDG-PET result obtain first-line chemotherapy . - Determine predictive value early negative FDG-PET result patient . - Correlate International Prognostic Index risk category FDG-PET result overall outcome patient . OUTLINE : This pilot study . - First-line chemotherapy : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 , oral prednisone day 1-5 , rituximab IV day 1 ( patient CD20-positive disease ) OR another standard first-line chemotherapy regimen . Treatment repeat every 14-21 day 2 3 course absence disease progression unacceptable toxicity . - Radiographic staging : Between day 11-20 course 2 3 OR day 11-13 course 3 first-line chemotherapy , patient receive fludeoxyglucose F 18 ( FDG ) IV . One hour later , patient undergo whole-body FDG-positron emission tomography ( PET ) CT scan . Patients evidence malignant disease FDG-PET ( i.e. , negative result ) receive standard treatment regimen may include localized radiotherapy limit stage bulky disease follow , 4-6 week later , repeat whole-body FDG-PET CT scan . Patients progressive disease first-line chemotherapy remove study . Patients evidence malignant disease FDG-PET ( i.e. , positive result ) stable disease well proceed ESHAP chemotherapy . - ESHAP chemotherapy : Patients receive etoposide IV 2 hour , methylprednisolone IV , cisplatin IV 3 hour day 1-4 followed cytarabine IV 2 hour day 5 . Patients CD20-positive disease also receive rituximab IV day 1 . Treatment repeat every 14-21 day 2 course absence disease progression unacceptable toxicity . Beginning 1 day completion course 2 , patient receive filgrastim ( G-CSF ) subcutaneously daily follow leukapheresis collect peripheral blood stem cell ( PBSC ) . Some patient may also undergo bone marrow ( BM ) harvest sufficient PBSC collect . Patients sufficient number stem cell proceed high-dose therapy autologous PBSC transplantation ( PBSCT ) BM transplantation ( BMT ) . - High-dose therapy PBSCT BMT : No 4 week completion PBSC collection BM harvest , patient receive high-dose therapy may include cyclophosphamide total-body irradiation OR busulfan cyclophosphamide . Patients undergo PBSCT BMT . Between 4-6 week completion PBSCT BMT , patient undergo repeat whole-body FDG-PET CT scan . Patients may also undergo consolidative radiotherapy sit bulky disease discretion physician . After completion study treatment , patient follow 4 week , every 3 month 2 year , every 6 month 1 year , annually 2 year . PROJECTED ACCRUAL : A total 55 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma 1 follow subtypes : Diffuse large Bcell lymphoma Mediastinal ( thymic ) Bcell lymphoma Grade 3 follicular lymphoma Anaplastic large cell lymphoma Peripheral Tcell lymphoma Must adequate stag disease follow technique : CT scan MRI affect site Bone marrow biopsy ( case result influence duration chemotherapy ) Lumbar puncture ( clinically indicate ) Stage IIV disease Any International Prognostic Index risk category Radiographically measurable disease None follow aggressive nonHodgkin 's subtypes allow : Mantle cell lymphoma Lymphoblastic lymphoma Burkitt 's lymphoma Mycosis fungoides/Sezary 's syndrome HTLV1associated Tcell leukemia/lymphoma Primary CNS lymphoma HIVassociated lymphoma Transformed lymphomas No prior diagnosis another hematologic malignancy No know progressive disease prior firstline chemotherapy No active CNS involvement lymphoma , except CNS involvement diagnosis previously treat remission PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 04 ( 02 peripheral blood stem cell [ PBSC ] bone marrow transplantation [ BMT ] patient ) Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3* Platelet count ≥ 75,000/mm^3 NOTE : *PBSC BMT patient Hepatic Bilirubin ≤ 2.0 mg/dL unless due Gilbert 's disease lymphoma* No known significant hepatic dysfunction expect improve would preclude PBSC BMT NOTE : *PBSC BMT patient Renal Creatinine ≤ 2.0 mg/dL* No known significant renal dysfunction expect improve would preclude PBSC BMT NOTE : *PBSC BMT patient Cardiovascular Ejection fraction ≥ 45 % echocardiogram MUGA* No known significant cardiac dysfunction expect improve would preclude PBSC BMT NOTE : *PBSC BMT patient ; cardiology consult evaluation may override ejection fraction criterion Pulmonary FEV_1 FVC ≥ 50 % predict patient receive thoracic mantle radiotherapy ( 75 % predict patient receive thoracic mantle radiotherapy ) * No known significant pulmonary dysfunction expect improve would preclude PBSC BMT NOTE : *PBSC BMT patient Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 3 year except carcinoma situ cervix nonmelanoma skin cancer No know HIV positivity OR HIV negative ( PBSC BMT patient ) No serious illness would preclude study participation No contraindication autologous BMT PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No 3 prior course chemotherapy lymphoma Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
</DOC>